Bone metastases occur frequently in patients with advanced cancer and are a serious complication of cancer. The decision to treat is often individualized, based on each patient's clinical presentation, life expectancy, and quality of life.
Methods
We reviewed the current literature pertaining to management of metastatic disease to bone, and the medical, radiotherapeutic, and surgical treatment options for management of bone metastasis are discussed.
Results
Current management of skeletal metastasis includes analgesia, systemic therapy, radiation therapy, and surgery. We propose treatment algorithms for management of vertebral and nonvertebral bone metastases and suggest individualized interventions based on clinical presentation.
Conclusions
Management of bone metastases is complex and requires a multidisciplinary approach. The goal of treatment is often palliative, and intervention and treatment regimens should be individualized based on the specific clinical presentation of each patient.
References
1.
MundyG.R.. Metastasis to bone: causes, consequences and therapeutic opportunities.Nat Rev Cancer.2002; 2(8): 584–593.
2.
ColemanR.E., RubensR.D.. The clinical course of bone metastases from breast cancer.Br J Cancer.1987; 55(1): 61–66.
3.
ResnickD., NiwayamaG.. Skeletal metastases. In: ResnickD., NiwayamaG., eds. Diagnosis of Bone and Joint Disorders.2nd ed.Philadelphia, PA: WB Saunders; 1988: 3945–4010.
4.
HiginbothamN.L., MarcoveR.C.. The management of pathological fractures.J Trauma.1965; 5(6): 792–798.
5.
RoodmanG.D.. Mechanisms of bone metastasis.N Engl J Med.2004; 350(16): 1655–1664.
6.
RoilaF., LupattelliM., SassiM.. Intra and interobserver variability in cancer patients’ performance status assessed according to Kar-nofsky and ECOG scales.Ann Oncol.1991; 2(6): 437–439.
PatchellR.A., TibbsP.A., RegineW.F.. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.Lancet.2005; 366(9486): 643–648.
9.
RosenthalD.I.. Radiologic diagnosis of bone metastases.Cancer.1997; 80(8 suppl): 1595–1607.
10.
SchafferD.L., PendergrassH.P.. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate.Radiology.1976; 121(2): 431–434.
11.
LudwigH., KumpanW., SinzingerH.. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis.Br J Radiol.1982; 55(651): 173–181.
12.
WoolfendenJ.M., PittM.J., DurieB.G.. Comparison of bone scintigraphy and radiography in multiple myeloma.Radiology.1980; 134(3): 723–728.
13.
RyanP.J., FogelmanI.. The bone scan: where are we now?Semin Nucl Med.1995; 25(2): 76–91.
14.
SavelliG., MaffioliL., MaccauroM.. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions.Q J Nucl Med.2001; 45(1): 27–37.
15.
SchweitzerM.E., LevineC., MitchellD.G.. Bull's-eyes and halos: useful MR discriminators of osseous metastases.Radiology.1993; 188(1): 249–252.
16.
UchidaN., SugimuraK., KajitaniA.. MR imaging of vertebral metastases: evaluation of fat saturation imaging.Eur J Radiol.1993; 17(2): 91–94.
17.
PomeranzS.J., PretoriusH.T., RamsinghP.S.. Bone scintigraphy and multimodality imaging in bone neoplasia: strategies for imaging in the new health care climate.Semin Nucl Med.1994; 24(3): 188–207.
18.
KaoC.H., HsiehJ.F., TsaiS.C.. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.Anticancer Res.2000; 20(3B): 2189–2192.
19.
GallowitschH.J., KresnikE., GasserJ.. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.Invest Radiol.2003; 38(5): 250–256.
20.
FogelmanI., CookG., IsraelO.. Positron emission tomography and bone metastases.Semin Nucl Med.2005; 35(2): 135–142.
21.
GrantF.D., FaheyF.H., PackardA.B.. Skeletal PET with 18F-fluoride: applying new technology to an old tracer.J Nucl Med.2008; 49(1): 68–78.
HetzelM., ArslandemirC., KönigH.H.. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.J Bone Miner Res.2003; 18(12): 2206–2214.
24.
AhmedzaiS., BrooksD.. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.J Pain Symptom Manage.1997; 13(5): 254–261.
25.
ChernyN.. New strategies in opioid therapy for cancer pain.J Oncol Manag.2000; 9(1): 8–15.
26.
ChernyN.I.. The management of cancer pain.CA Cancer J Clin.2000; 50(2): 70–116; quiz 117-120.
27.
SloanP.A., MoulinD.E., HaysH.. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain.J Pain Symptom Manage.1998; 16(2): 102–111.
GourlayD.L., HeitH.A., AlmahreziA.. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain.Pain Med.2005; 6(2): 107–112.
30.
RosenL.S.. Angiogenesis inhibition in solid tumors.Cancer J.2001; 7(suppl 3): S120–S128.
31.
SaadF., ChiK., FleshnerN.. The role of bisphosphonates in the management of bone metastases in prostate cancer.Can J Urol.2004; 11(5): 2376–2382.
32.
RosenL.S., GordonD., KaminskiM.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.Cancer.2003; 98(8): 1735–1744.
33.
BodyJ.J., DielI.J., LichinitzerM.. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.Br J Cancer.2004; 90(6): 1133–1137.
34.
CarteniG., BordonaroR., GiottaF.. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.Oncologist.2006; 11(7): 841–848.
35.
BodyJ.J., BartlR., BurckhardtP.. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.J Clin Oncol.1998; 16(12): 3890–3899.
36.
StopeckA.T., LiptonA., BodyJ.J.. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.J Clin Oncol.2010; 28(35): 5132–5139.
37.
HenryD.H., CostaL., GoldwasserF.. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.J Clin Oncol.2011; 29(9): 1125–1132.
38.
FizaziK., CarducciM., SmithM.. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.Lancet.2011; 377(9768): 813–822.
39.
ChowE., HarrisK., FanG.. Palliative radiotherapy trials for bone metastases: a systematic review.J Clin Oncol.2007; 25(11): 1423–1436.
40.
ChowE.. Update on radiation treatment for cancer pain.Curr Opin Support Palliat Care.2007; 1(1): 11–15.
41.
BlitzerP.H.. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis.Cancer.1985; 55(7): 1468–1472.
42.
SteenlandE., LeerJ.W., van HouwelingenH.. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study.Radiother Oncol.1999; 52(2): 101–109.
43.
HartsellW.F., ScottC.B., BrunerD.W.. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases.J Natl Cancer Inst.2005; 97(11): 798–804.
44.
8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party.Radiother Oncol.1999; 52(2): 111–121.
45.
Foro ArnalotP., FontanalsA.V., GalceránJ.C.. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction.Radiother Oncol.2008; 89(2): 150–155.
46.
JeremicB., ShibamotoY., AcimovicL.. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain.Int J Radiat Oncol Biol Phys.1998; 42(1): 161–167.
47.
KaasaS., BrenneE., LundJ.A.. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases.Radiother Oncol.2006; 79(3): 278–284.
48.
KoswigS., BudachV.. [Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy): a prospective study].Strahlenther Onkol.1999; 175(10): 500–508.
49.
RoosD.E., TurnerS.L., O'BrienP.C.. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).Radiother Oncol.2005; 75(1): 54–63.
50.
SandeT.A., RuenesR., LundJ.A.. Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial.Radiother Oncol.2009; 91(2): 261–266.
51.
WuJ.S., WongR., JohnstonM.. Meta-analysis of dose-fraction-ation radiotherapy trials for the palliation of painful bone metastases.Int J Radiat Oncol Biol Phys.2003; 55(3): 594–605.
52.
SzeW.M., ShelleyM., HeldI.. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials.Cochrane Database Syst Rev.2004(2): CD004721.
53.
LutzS., BerkL., ChangE.. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline.Int J Radiat Oncol Biol Phys.2011; 79(4): 965–976.
54.
GersztenP.C., BurtonS.A., OzhasogluC.. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution.Spine (Phila Pa 1976).2007; 32(2): 193–199.
55.
YamadaY., MatsumotoT., ArakawaA.. Evaluation using a combination of lymphatic invasion on D2-40 immunostain and depth of dermal invasion is a strong predictor for nodal metastasis in extramammary Paget's disease.Pathol Int.2008; 58(2): 114–117.
56.
MouldingH.D., ElderJ.B., LisE.. Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases.J Neurosurg Spine.2010; 13(1): 87–93.
57.
JinR., RockJ., JinJ.Y.. Single fraction spine radiosurgery for myeloma epidural spinal cord compression.J Exp Ther Oncol.2009; 8(1): 35–41.
58.
HaleyM.L., GersztenP.C., HeronD.E.. Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis.J Neurosurg Spine.2011; 14(4): 537–542.
59.
SalazarO.M., SandhuT., da MottaN.W.. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA).Int J Radiat Oncol Biol Phys.2001; 50(3): 765–775.
60.
RoquéI, FigulsM., Martinez-ZapataM.J., Scott-BrownM.. Radioisotopes for metastatic bone pain.Cochrane Database Syst Rev.2011; (7): CD003347.
61.
SilbersteinE.B., TaylorATJrEANM. EANM procedure guidelines for treatment of refractory metastatic bone pain.Eur J Nucl Med Mol Imaging.2003; 30(3): BP7–BP11.
62.
PaesF.M., SerafiniA.N.. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain.Semin Nucl Med.2010; 40(2): 89–104.
63.
PerezC.A., CosmatosD., GarciaD.M.. Irradiation in relapsing carcinoma of the prostate.Cancer.1993; 71(3 suppl): 1110–1122.
64.
PorterA.T., McEwanA.J.. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.Semin Oncol.1993; 20(3 suppl 2): 38–43.
65.
HeronD.E., BrufskyA., BeriwalS.. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy.Ann Oncol.2008; 19(9): 1639–1643.
66.
RobinsonR.G., PrestonD.F., SchiefelbeinM.. Strontium 89 therapy for the palliation of pain due to osseous metastases.JAMA.1995; 274(5): 420–424.
67.
VassiliouV., BrulandO., JanjanN.. Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness.Clin Oncol (R Coll Radiol).2009; 21(9): 665–667.
68.
VassiliouV., KardamakisD.. The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: from theory to clinical practice.Anticancer Agents Med Chem.2009; 9(3): 326–335.
69.
HaentjensP., CasteleynP.P., OpdecamP.. Evaluation of impending fractures and indications for prophylactic fixation of metastases in long bones: review of the literature.Acta Orthop Belg.1993; 59(suppl 1): 6–11.
70.
TancioniF., LorenzettiM.A., NavarriaP.. Percutaneous vertebral augmentation in metastatic disease: state of the art.J Support Oncol.2011; 9(1): 4–10.
71.
JenisL.G., DunnE.J., AnH.S.. Metastatic disease of the cervical spine: a review.Clin Orthop Relat Res.1999; (359): 89–103.
